Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
- Bill Number
- S. 735
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-02-26: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-02-05T17:34:02Z
AI-Generated Summary
Purpose
The legislation, titled the "Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025," aims to reauthorize and enhance a federal demonstration program under the Public Health Service Act. It focuses on improving the treatment of sickle cell disease—a genetic blood disorder that causes red blood cells to become misshapen and block blood flow—while expanding efforts to prevent and treat its complications. It also encourages broader research into heritable blood disorders (inherited conditions affecting blood cells).
Key Provisions
- Expanded Program Scope: Updates the program's focus from general prevention and treatment of sickle cell disease to specifically include the treatment of the disease itself and the prevention and management of its complications, such as pain crises, infections, and organ damage.
- Funding Mechanisms: Allows the Secretary of Health and Human Services (HHS) to provide support through grants (direct funding awards), contracts, or cooperative agreements (collaborative partnerships) to eligible organizations, rather than limiting to contracts only.
- Increased Funding: Allocates $8,205,000 annually for fiscal years 2025 through 2029 to support the program, up from previous levels.
- Sense of Congress Statement: Expresses congressional support for additional research to better understand the causes of heritable blood disorders, including sickle cell disease, and to develop potential cures.
Significant Changes to Existing Law
- Amends Section 1106(b) of the Public Health Service Act (42 U.S.C. 300b-5(b)), which previously authorized a demonstration program through fiscal year 2023 with lower funding ($4,455,000 per year) and narrower language limited to "prevention and treatment of sickle cell disease."
- Broadens eligibility for federal support by including grants and cooperative agreements alongside contracts.
- Shifts emphasis to explicitly address complications of sickle cell disease, reflecting a more comprehensive approach to managing the condition's long-term effects.
- Extends and increases funding authorization to cover fiscal years 2025–2029, effectively reauthorizing the program for five more years with nearly double the annual budget.
Potential Impacts
- Government Agencies: The Department of Health and Human Services (HHS) will manage expanded funding and partnerships, potentially increasing administrative workload but enabling more flexible program implementation to reach underserved communities.
- Citizens: Individuals with sickle cell disease (primarily affecting African Americans and other groups of African descent) and other heritable blood disorders may benefit from improved access to treatments, complication prevention, and research-driven advancements, leading to better health outcomes and reduced healthcare disparities.
- International Relations: Minimal direct impact, though enhanced U.S. research could indirectly support global health efforts, as sickle cell disease affects populations worldwide, particularly in Africa and the Middle East.
Main Stakeholders Affected
- Patients and Families: Those living with sickle cell disease or other heritable blood disorders, who stand to gain from expanded treatment and prevention services.
- Healthcare Providers and Organizations: Community health centers, hospitals, and nonprofits eligible for grants or agreements to deliver care and education.
- Research Institutions: Universities and medical researchers focused on blood disorders, encouraged by the call for further studies on causes and cures.
- Federal Government: HHS and congressional committees (e.g., Health, Education, Labor, and Pensions) overseeing program funding and evaluation.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens existing public health authority under the Public Health Service Act without creating new mandates; the inclusion of grants and cooperative agreements provides HHS with more tools for efficient program delivery, potentially reducing legal challenges related to funding restrictions.
- Constitutional: Aligns with Congress's spending power under Article I, Section 8, to promote general welfare through health programs; no apparent conflicts with federalism, as it focuses on national research and demonstration initiatives.
- Political: Bipartisan sponsorship (by Senators Scott and Booker) highlights cross-party support for addressing health disparities in minority communities; the funding increase signals growing federal priority on rare diseases, but success depends on annual appropriations, which could face budget debates.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (3)
Sen. Booker, Cory A. [D-NJ], Sen. Warnock, Raphael G. [D-GA], Sen. Ossoff, Jon [D-GA]
Recent Actions
- 2025-02-26: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-02-26: Introduced in Senate
Bill Versions
- Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 — issued 2025-02-26 — PDF (3 pages)